title: Viral hepatitis: Cost-effectiveness of direct-acting antivirals for chronic hepatitis C.
abstract: A new study has reported the long-term effectiveness and cost-effectiveness of the direct-acting antivirals telaprevir and boceprevir for the treatment of chronic hepatitis C. These findings have the potential to be used to guide clinical and reimbursement decisions for treating populations with a high prevalence of HCV infection.
authors: Department of Public Health and Health Technology Assessment, UMIT (University for Health Sciences, Medical Informatics and Technology), Eduard Wallnoefer Center I, A-6060 Hall in Tirol, Austria.
authors: Gaby
authors: G
authors: Sroczynski
authors: Uwe
authors: U
authors: Siebert
mesh_terms: D000998:Antiviral Agents / Q000191:economics* / Q000627:therapeutic use*; D005260:Female; D016174:Hepacivirus / Q000145:classification* / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000191:economics*; D006801:Humans; D008297:Male; D058014:Veterans Health
chemical_list: D000998:Antiviral Agents
references: Ann Intern Med. 2012 Feb 21;156(4):279-90
references: 22351713
references: Med Decis Making. 2012 Sep-Oct;32(5):690-700
references: 22990084
references: Int J Technol Assess Health Care. 2008 Summer;24(3):244-58; discussion 362-8
references: 18601792
references: Antivir Ther. 2012;17(6 Pt B):1189-99
references: 23186646
references: Int J Technol Assess Health Care. 2005 Winter;21(1):55-65
references: 15736515
references: Clin Gastroenterol Hepatol. 2013 Nov;11(11):1503-10
references: 23707354
references: J Viral Hepat. 2010 Jan;17(1):34-50
references: 19656290
references: Expert Opin Investig Drugs. 2013 Sep;22(9):1107-21
references: 23735127